Open AccessCost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
Author(s) -
Dimple Butani,
Nidhi Gupta,
Gaurav Jyani,
Pankaj Bahuguna,
Rakesh Kapoor,
Shankar Prinja
Publication year - 2021
Publication title -
breast cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.19
H-Index - 27
ISSN - 1179-1314
DOI - 10.2147/bctt.s331831
Subject(s) - medicine , tamoxifen , aromatase inhibitor , breast cancer , aromatase , surgical oncology , oncology , postmenopausal women , adjuvant , anastrozole , adjuvant therapy , hormone receptor , hormone therapy , endocrine system , oestrogen receptor , gynecology , cancer , hormone
Breast cancer is the leading cause of cancer among women in India. Treatment with hormone therapy reduces recurrence. We undertook this cost-effectiveness study to ascertain the treatment option offering the best value for money.